R-CEOP Regimen

specific

A regimen consisting of cyclophosphamide, etoposide, vincristine, prednisone and rituximab that may be used in the treatment of diffuse large B-cell lymphoma (DLBCL) and post-transplant lymphoproliferative disorders.

Top Centers for R-CEOP Regimen

Ranked by research excellence score (trials · grants · publications). Methodology →

No centers currently specializing in this cancer type.

Research tier badges reflect trial volume, NIH grant funding, and publication impact — not clinical outcomes or patient satisfaction. Learn about our methodology →